Business
Hershey’s sales and profit
Sherwood News

Mondelez has a serious sweet spot for Hershey’s recession-resistant chocolate business

Mondelez has made a preliminary approach about a potential acquisition of Hershey, again.

Mondelez, the owner of Cadbury, Oreo, Chips Ahoy, and more, is getting sweet on the 130-year-old Hershey Co., as the food giant is exploring an acquisition of the ever-profitable chocolate maker, per Bloomberg.

It isn’t the first time that the packaged-food company has tried to acquire Hershey. In 2016, Mondelez tried to sweet-talk the chocolate company into a tie-up with a $23 billion bid, but execs eventually had to go home empty-handed after the majority-owning Hershey Trust Co. rejected the offer. Since then, Hershey’s stock has more than doubled, which is why this latest offer would have to be at a significantly higher price: Hershey Co.’s enterprise value (including debt) is some $43.8 billion.

But there’s a reason why Mondelez might think it’s worth digging that deep into its pockets. With a few small exceptions — including this year, which will likely see a slight hit on profits from record-high cocoa costs — Hershey tends to always find a way to sell more chocolate and make a bigger bottom line... even through major global recessions.

The potential takeover only gets sweeter when you consider that the Chicago-based food firm already owns two of Europe’s top chocolate brands: Cadbury and Milka. Acquiring Hershey would consolidate the industry significantly, bringing the biggest name in the world of American chocolates — in 2022, Hershey reportedly had 36% of the market share in the US — into Mondelez’s portfolio. Being bigger makes negotiating those all-important cocoa and commodity contracts a bit easier.

The deal would be the latest in a long line of confection deals, as the industry grapples with the uncertainty of the potential impact of GLP-1 appetite suppressants like Ozempic. In August, Mars, the world’s largest chocolate company, agreed to a $35.9 billion deal to buy Kellanova.

More Business

See all Business
business

Ford reportedly in talks to buy hybrid vehicle batteries from Chinese auto giant BYD

Detroit’s Ford and China’s BYD are said to be in ongoing talks to partner on an agreement that would see Ford buy hybrid vehicle batteries from BYD, according to reporting from The Wall Street Journal.

The report comes just days after President Trump toured a Ford factory in Michigan and implied openness to Chinese automakers coming to the US.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

Still life of Ozempic and Wegovy with weight scale.

Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s

Novo Nordisk CEO Mike Doustdar estimated that around 1.5 million US patients are using compounded versions of the company’s drugs.

Handshake

Big Pharma enters 2026 with an appetite for deals

At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.